Ian  Taylor net worth and biography

Ian Taylor Biography and Net Worth

Insider of Arvinas

Dr. Taylor is the Chief Scientific Officer at Arvinas. He came to the Company after nearly 10 years at Pfizer Oncology, most recently as an Early Development Team Leader. In this role, Dr. Taylor was responsible for leading a cross-functional drug development team that conducted Phase 1 and Phase 2 clinical trials for multiple assets in several cancer indications. His initial role at Pfizer Oncology was as Senior Director of Translational Oncology. In this role, he was responsible for directing translational science activities, which included designing and executing translational research plans and leading companion diagnostic partnerships for programs in both preclinical and clinical (Phase 1 -3) stages.

Prior to Pfizer, Dr. Taylor worked at Bayer Healthcare, Pharmaceuticals, holding positions of increasing responsibility, including Vice President of Cancer Biology. In this position, he led the department responsible for all biology aspects of small molecule drug discovery of cancer therapeutics in the mechanistic areas of signal transduction, cell cycle regulation, angiogenesis and apoptosis. During his tenure, the Cancer Biology group delivered numerous molecules to the Development organization. He also started and led the Biomarker group, which contributed to the development of sorafenib.

Dr. Taylor earned his B.A. from Bowdoin College and his Ph.D. in Molecular Biology and Genetics from Harvard University. He also completed his postdoctoral training in the laboratory of Dr. Harold Varmus at the University of California, San Francisco and the National Institutes of Health (NIH).

What is Ian Taylor's net worth?

The estimated net worth of Ian Taylor is at least $1.88 million as of March 1st, 2023. Dr. Taylor owns 101,721 shares of Arvinas stock worth more than $1,879,804 as of December 21st. This net worth approximation does not reflect any other investments that Dr. Taylor may own. Additionally, Dr. Taylor receives a salary of $732,260.00 as Insider at Arvinas. Learn More about Ian Taylor's net worth.

How old is Ian Taylor?

Dr. Taylor is currently 61 years old. There are 8 older executives and no younger executives at Arvinas. The oldest executive at Arvinas is Dr. John A. Grosso Ph.D., Senior Vice President of R&D Technical Operations, who is 67 years old. Learn More on Ian Taylor's age.

What is Ian Taylor's salary?

As the Insider of Arvinas, Inc., Dr. Taylor earns $732,260.00 per year. The highest earning executive at Arvinas is Dr. John G. Houston Ph.D., Chairperson, CEO & President, who commands a salary of $1,140,000.00 per year. Learn More on Ian Taylor's salary.

How do I contact Ian Taylor?

The corporate mailing address for Dr. Taylor and other Arvinas executives is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. Arvinas can also be reached via phone at (203) 535-1456 and via email at [email protected]. Learn More on Ian Taylor's contact information.

Has Ian Taylor been buying or selling shares of Arvinas?

Ian Taylor has not been actively trading shares of Arvinas during the past quarter. Most recently, Ian Taylor sold 1,051 shares of the business's stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $29.53, for a transaction totalling $31,036.03. Following the completion of the sale, the insider now directly owns 101,721 shares of the company's stock, valued at $3,003,821.13. Learn More on Ian Taylor's trading history.

Who are Arvinas' active insiders?

Arvinas' insider roster includes Sean Cassidy (CFO), John Houston (CEO), Bradley Margus (Director), Briggs Morrison (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Timothy Shannon (Director), and Ian Taylor (Insider). Learn More on Arvinas' active insiders.

Are insiders buying or selling shares of Arvinas?

In the last year, insiders at the sold shares 3 times. They sold a total of 8,597 shares worth more than $404,488.85. The most recent insider tranaction occured on February, 23rd when CEO John G Houston sold 5,196 shares worth more than $244,471.80. Insiders at Arvinas own 5.2% of the company. Learn More about insider trades at Arvinas.

Information on this page was last updated on 2/23/2024.

Ian Taylor Insider Trading History at Arvinas

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2023Sell1,051$29.53$31,036.03101,721View SEC Filing Icon  
3/4/2022Sell869$63.94$55,563.86View SEC Filing Icon  
2/15/2022Sell20,000$73.02$1,460,400.00View SEC Filing Icon  
11/15/2021Sell20,000$84.04$1,680,800.00View SEC Filing Icon  
8/16/2021Sell20,000$87.30$1,746,000.0098,645View SEC Filing Icon  
4/5/2021Sell25,000$66.81$1,670,250.00103,645View SEC Filing Icon  
3/2/2021Sell894$77.45$69,240.3079,539View SEC Filing Icon  
3/19/2020Sell826$37.61$31,065.8671,224View SEC Filing Icon  
11/13/2019Sell10,000$28.00$280,000.0055,496View SEC Filing Icon  
9/30/2019Sell10,000$21.86$218,600.00
3/29/2019Buy1,000$14.66$14,660.00View SEC Filing Icon  
See Full Table

Ian Taylor Buying and Selling Activity at Arvinas

This chart shows Ian Taylor's buying and selling at Arvinas by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arvinas Company Overview

Arvinas logo
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Read More

Today's Range

Now: $18.48
Low: $17.53
High: $18.70

50 Day Range

MA: $24.83
Low: $17.83
High: $28.04

2 Week Range

Now: $18.48
Low: $17.37
High: $53.08

Volume

1,763,635 shs

Average Volume

738,855 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.82